Agfa lands large PACS sale
Agfa Medical has received a letter of intent for a large-scale Impax installation from the University of Maryland Medical System. The Ridgefield Park, NJ-based film and PACS company will use the Impax network to link up the hospital's radiology, ER, and
Agfa Medical has received a letter of intent for a large-scale Impax installation from the University of Maryland Medical System. The Ridgefield Park, NJ-based film and PACS company will use the Impax network to link up the hospital's radiology, ER, and ICU departments, as well as doctor's offices and the hospital's shock trauma center. When completed, the network will cover 38 areas in five buildings and will employ 130 cable lines.
Integration with the hospital's IDXRad radiology information system will be performed, allowing physicians access to patient reports and images on 19 diagnostic review stations and 42 clinician stations, according to Agfa. The company's Web 1000 Java-based server offering will also be installed at several dozen locations on the premises. Agfa CR systems will be placed in the main radiology department, as well as the ER and the shock trauma center.
Installation of the network is scheduled to begin this month, with the first phase scheduled for completion before the 1998 Society for Computer Applications in Radiology meeting, which will be held in June at UMMS.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
